country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-175027

Copy Link Print Information

RIPK1-IN-33

RIPK1-IN-33 is a blood-brain barrier-permeable and orally active RIPK1 inhibitor, with an IC₅₀ of 0.115 μM. RIPK1-IN-33 demonstrates remarkable anti-ferroptosis activity, radical scavenging capacity (IC₅₀ = 123.3 μM), and anti-lipid peroxidation effects (IC₅₀ = 9.72 μM). RIPK1-IN-33 markedly reduces cerebral infarction volume and improves neurological function scores in transient middle cerebral artery occlusion (tMCAO) model. RIPK1-IN-33 can be used for the study of ischemic stroke.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₂₆H₂₇F₂N₅O₂
분자량:479.52

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

RIPK1-IN-33 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All RIP kinase Isoforms :

In Vitro

RIPK1-IN-33 (Compound 23a) (30-60 min) demonstrates remarkable radical scavenging DAPH capacity (IC₅₀ = 123.3 μM), and antioxidant MDA effects (IC₅₀ = 9.72 μM)^[1].
RIPK1-IN-33 (0.0076-50 μM, 17 h) dose-dependently reduces the mRNA expression level of PTGS2 (IC₅₀ = 0.156 μM) in HT-1080 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

HT-1080 cells
Concentration:

0.0076, 0.0227, 0.0686, 0.206, 0.617, 1.9, 5.6, 16.7, 50 μM
Incubation Time:

17 h
Result:

Reduced the mRNA expression level of PTGS2 (IC₅₀ = 0.156 μM) in HT-1080 cells.
Displayed markedly superior anti-ferroptotic activity compared to Edaravone (HY-B0099) (IC₅₀ = 4.92 μM).

Parmacokinetics

Species	Dose	Route	C_max	T_max	AUC_last	F	T_1/2
Dog^[1]	10 mg/kg	i.g.	3484 ng/mL	0.25 h	3588 ng·h/mL	26.8 %	/
Dog^[1]	5 mg/kg	i.v.	9334 ng/mL	/	6702 ng/L.h	/	7.98 h
Rat^[1]	16.5 mg/kg	i.v.	8657 ng/mL	/	3194 ng/L.h	/	5.17 h
Rat^[1]	165 mg/kg	i.g.	12838 ng/mL	0.25 h	7065 ng/L.h	44.3 %	/

In Vivo

RIPK1-IN-33 (Compound 23a) (33 mg/kg (68.8 μmol/kg), i.v., twice doses, 24 h) exerts a protective effect in a rat model of cerebral ischemia-reperfusion injury^[1].
RIPK1-IN-33 (Compound 23a) (100-200 mg/kg, i.v., single dose or once daily for 7 days) exhibits no mortality or significant adverse events in a rat model of cerebral ischemia-reperfusion injury^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Sprague-Dawley rats (200-230 g) subjected to transient middle cerebral artery occlusion (tMCAO)^[1]
Dosage:

33 mg/kg (68.8 μmol/kg)
Administration:

i.v. for twice doses and the second dose was administered 6 h later
Result:

Reduced infarct volume in tMCAO rats compared to the vehicle control.
Improved neurological function in tMCAO rats.
Downregulated MDA level.
Reduced the protein expression of necroptosis-associated caspase-3 in the ischemic penumbra.
Downregulated the protein expression of cyclooxygenase-2 (COX-2, encoded by PTGS2).
Upregulated glutathione peroxidase 4 (GPX4) within the ferroptosis pathway.

Animal Model:

Adult male Sprague-Dawley rats (200-230 g) subjected to transient middle cerebral artery occlusion (tMCAO)^[1]
Dosage:

100, 200 mg/kg
Administration:

i.v. for a single dose or i.v. once daily for 7 days
Result:

Showed no abnormalities in body weight, food consumption, organ-to-body weight ratios, blood biochemical parameters, or gross necropsy findings.

Related Protocols :

Ferroptosis Solutions

Chemical Information

분자량 479.52
화학식 C₂₆H₂₇F₂N₅O₂
SMILES

FC1=CC([C@@H]2CC=NN2C(C3CCN(CC4=CC=CC(N5C(CC(C)=N5)=O)=C4)CC3)=O)=CC(F)=C1
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Song Z, et al. Targeting RIPK1-mediated necroptosis, oxidative stress, and ferroptosis: A novel multitarget therapy for ischemic stroke. Eur J Med Chem. 2025 Oct 15;296:117884. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기